Does Wegovy Cause Bruising?
Wegovy is given as a subcutaneous injection, so small skin reactions at the injection site are part of the territory. Bruising is one of them, and it is usually the one that worries people most because it is visible.
This article explains why a bruise appears after an injection, how common injection site reactions actually are in the trial data, what reduces the risk, and which signs are worth a call to your healthcare provider rather than a wait-and-see approach.
Medical disclaimer. This article is educational and does not replace individualized medical advice. Wegovy is a prescription medicine, and any concern about an injection site reaction should be raised with the prescribing healthcare professional.
How Common Are Injection Site Reactions?
Less common than the internet suggests. In the adult clinical trials behind the Wegovy label, 1.4% of patients treated with Wegovy experienced injection site reactions, including itching, redness, inflammation, induration and irritation, compared with 1.0% of patients on placebo.
That gap is small, and it is worth keeping in perspective: the reactions patients report most often with semaglutide are gastrointestinal, not cutaneous. A bruise at the injection site is usually a consequence of the needle rather than of the medicine.
Why Bruising Happens
A bruise forms when the needle nicks a small blood vessel in the subcutaneous tissue and a little blood escapes into the surrounding area. This can happen with any subcutaneous injection and is not specific to semaglutide. The result is a tender, discoloured patch that usually fades over several days to about a week without any treatment, and it does not reduce how well the dose works.
Some people bruise more readily than others. Thinner subcutaneous fat, fragile capillaries, older age and medicines that affect clotting all make a visible bruise more likely from the same injection technique.
Technique and Site Selection
Most of what can be controlled sits in the injection itself. The table below separates the habits that reduce bruising from the ones that cause it.
| Do | Avoid |
|---|---|
| Inject into the fatty tissue of the abdomen, thigh or upper arm | Injecting into scars, hard lumps or visible veins |
| Use a new sterile needle for every dose | Reusing a needle, which blunts the tip and increases tissue trauma |
| Let the alcohol dry fully before injecting | Injecting through damp skin, which stings and can bleed more |
| Press gently with a clean tissue for 10 to 20 seconds afterwards | Rubbing the site, which spreads any bleeding under the skin |
| Move to a fresh spot at least a finger-width from the last one | Using the same small patch of skin week after week |
If you are new to self-injection, the step-by-step sequence is covered in our guide on how to inject Wegovy.
Ways to Reduce the Risk
Check what else you are taking
Prescription anticoagulants and antiplatelet medicines raise bleeding risk, and so do aspirin, ibuprofen, naproxen and supplements such as vitamin E, fish oil and ginkgo. None of these is a reason to stop Wegovy, but they do explain why some people bruise more, and they are worth mentioning to your prescriber.
Use a cold compress
A wrapped cold pack applied for up to 15 minutes before the injection constricts local blood vessels, and the same can be repeated afterwards. Keep a cloth between the ice and the skin and do not exceed 15 minutes at a time.
Rotate sites properly
Rotation means a genuinely different spot each week, not a different corner of the same patch. Staying within one region such as the abdomen is fine, provided each injection lands at least a finger-width from the previous one. Consistent rotation also prevents the firm fatty lumps that develop in overused areas and that absorb medication unpredictably.
Slow down the injection
Rapid needle insertion and fast delivery cause more tissue trauma, particularly in areas with less subcutaneous fat. Steady pressure, without pushing the pen against the skin, is gentler on the tissue.
Ask for a demonstration
If technique feels uncertain, a nurse or pharmacist can watch you inject once and correct the small things. That single session usually solves more than any amount of reading.
When to Contact Your Healthcare Provider
Most bruising resolves on its own. Contact your provider if you notice:
- A bruise larger than about two inches across, or one that keeps growing after the first 24 hours;
- Severe pain at the site that interferes with normal activities or has not started improving within 48 hours;
- Signs of infection: spreading redness, increasing warmth, pus or drainage, or a temperature above 100.4 degrees Fahrenheit (38 degrees Celsius);
- Bruising that persists beyond three weeks without clearly fading;
- A firm lump under the skin that does not gradually resolve;
- A sudden change in your usual pattern, with bruises becoming larger, more frequent or more painful;
- Bruising alongside unexplained bleeding elsewhere, such as bleeding gums, frequent nosebleeds or blood in urine or stool.
The last point matters most. Bruising confined to injection sites is a local issue; bruising combined with bleeding elsewhere is a systemic one and deserves prompt assessment.
Other Reactions to Expect
Wegovy is a GLP-1 receptor agonist used for chronic weight management, and its common adverse effects are largely gastrointestinal: nausea, vomiting, diarrhea and constipation, typically most noticeable early in treatment and after each dose increase. These usually settle as the body adapts, which is the same pattern seen across the drug class and described in our overview of GLP-1 side effects.
Serious reactions are rare but real, and hypersensitivity symptoms, severe abdominal pain or signs of low blood sugar warrant medical attention rather than watchful waiting.
The Bottom Line
Occasional bruising after a Wegovy injection is a minor, short-lived consequence of putting a needle through skin, not a sign that something has gone wrong with the medication. Small bruises fade within days and do not affect the dose.
Good technique, honest site rotation and avoiding tissue that is already sore or discoloured remove most of the risk. Everything beyond that, particularly a change in your usual pattern, is a conversation with your provider rather than something to manage alone.
FAQs
Is bruising a listed side effect of Wegovy?
Injection site reactions are listed, covering itching, redness, inflammation, induration and irritation, and they affected 1.4% of adults in the clinical trials against 1.0% on placebo. Bruising specifically is usually mechanical, caused by the needle catching a small vessel rather than by semaglutide itself.
How long does a bruise from an injection last?
Typically several days to about a week, sometimes up to two weeks for a larger one. A bruise that has not visibly improved after three weeks should be reviewed by a healthcare professional.
Does bruising mean the dose did not work?
No. A bruise reflects a small amount of bleeding in the tissue and does not change absorption of the medication or reduce its effect.
Which injection site bruises least?
There is no universally best site. The abdomen is the most commonly used because the fat layer is consistent and the area is large enough for genuine rotation, but the thigh and upper arm are also approved sites. What reduces bruising is rotation and technique rather than the region itself.
Should the site be rubbed after injecting?
No. Gentle pressure with a clean tissue for 10 to 20 seconds is enough. Rubbing spreads any bleeding under the skin and makes the resulting bruise larger.
Can a cold pack be used on an existing bruise?
Yes, for up to 15 minutes at a time with a cloth between the ice and the skin. Applied before the injection it can also help constrict the vessels and reduce the chance of a new bruise.
Where can Wegovy be bought with a prescription?
Patients with a valid prescription can order Wegovy from Insulin.store, shipped from Canada across the full dose range, including the 0.25 mg starting pen.
References
Novo Nordisk. (2024). WEGOVY (semaglutide) injection, for subcutaneous use: highlights of prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
Frid, A. H., Kreugel, G., Grassi, G., et al. (2016). New insulin delivery recommendations. Mayo Clinic Proceedings, 91(9), 1231-1255. https://doi.org/10.1016/j.mayocp.2016.06.010
Zou, P., Wang, F., Wang, J., et al. (2021). Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. Journal of Controlled Release, 336, 310-321. https://doi.org/10.1016/j.jconrel.2021.06.038